People
Filter News
Found 62,397 articles
-
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
3/18/2024
Checkpoint Therapeutics, Inc. today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately.
-
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
3/18/2024
Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
-
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
3/18/2024
Syndax Pharmaceuticals, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately.
-
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
3/18/2024
Chromocell Therapeutics Corp. today announced that its interim CEO Frank Knuettel, has been appointed as the Company’s permanent CEO.
-
Circular Genomics Adds Dr. Michael Ackermann, PhD, MBA to its Scientific Advisory Board
3/18/2024
Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced the addition of Michael F. Ackermann, PhD, MBA to its Scientific Advisory Board (SAB).
-
Abcam appoints Markus Lusser as new President
3/18/2024
Abcam today announced the appointment of Markus Lusser as President.
-
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
3/18/2024
Fulcrum Therapeutics, Inc.® announced the appointment of Patrick Horn, M.D., Ph.D., as chief medical officer, effective immediately.
-
GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer
3/18/2024
GRO Biosciences Inc., an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, announced the expansion of its leadership with the hire of Tracey Lodie, PhD as Chief Development Officer.
-
Lucas Vitale Joins Orthofix as Chief People and Business Operations Officer
3/18/2024
Orthofix Medical Inc., a leading global spine and orthopedics company, announced that Lucas Vitale has joined the company in the newly created role of Chief People and Business Operations Officer.
-
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
3/18/2024
Oragenics, Inc. announced it has appointed Dr. James “Jim” Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial.
-
Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer
3/18/2024
Everest Medicines announced that the company has strengthened its management team with the appointments of Ms. Sandra Zeng as Chief Medical Officer and Mr. Rico Liang as Chief Product Officer.
-
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
3/18/2024
Ocugen, Inc. announced the appointment of Dr. Huma Qamar as Chief Medical Officer.
-
Parexel Announces CEO Succession PlanChief Operating & Growth Officer Peyton Howell to succeed Jamie Macdonald effective May 15, 2024
3/18/2024
Parexel today announced that Jamie Macdonald will retire and transition his role as Chief Executive Officer (CEO) to the company’s Chief Operating and Growth Officer Peyton Howell effective May 15, 2024.
-
Cellino Announces Ed Tekeian as Senior Vice President of Engineering
3/18/2024
Cellino Biotech, Inc. today announced the expansion of its executive leadership team with the addition of Ed Tekeian as Senior Vice President of Engineering.
-
Dignify Therapeutics Announces Anthony DiTonno as Chief Executive Officer
3/18/2024
Dignify Therapeutics, a pharmaceutical and medical device development company focused on restoring bowel and bladder control for elderly and neurologically impaired individuals, announced that Anthony DiTonno has been named as Chief Executive Officer.
-
Nodexus Names William Rhodes Executive Chairman of the Board
3/18/2024
Nodexus Inc. today announced that William (Bill) Rhodes has been named Executive Chairman of the company’s Board of Directors.
-
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 15, 2024
3/15/2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 11, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 8,904 shares of common stock and 5,461 restricted stock units (“RSUs”) to three new employees under Acadia’s 2023 Inducement Plan.
-
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 15, 2024
3/15/2024
Scholar Rock today announced that the company granted inducement equity awards on March 11, 2024, covering an aggregate of 201,469 shares of its common stock to six newly hired employees.
-
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
3/14/2024
Lexaria Bioscience Corp. announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately.
-
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
3/14/2024
Y-mAbs Therapeutics, Inc. today announced that Chief Financial Officer, Bo Kruse, has notified the Company of his resignation.